OTC Rogaine marketing exclusivity challenged in petition to FDA from D.C. law firm.
This article was originally published in The Tan Sheet
Executive Summary
OTC ROGAINE THREE-YEAR MARKET EXCLUSIVITY CONTESTED by Washington, D.C. law firm Hyman, Phelps & McNamara in a Jan. 18 petition submitted to FDA. Filed on behalf of an unnamed client "that intends to market minoxidil for the treatment of baldness," the petition maintains that the data presented by Pharmacia & Upjohn in support of its Rx-to-OTC switch application fails to include "any new and essential clinical investigation."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning